Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics
This article was originally published in The Pink Sheet Daily
Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.
You may also be interested in...
Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.